Lim WXJGammon CSvon Hurst PChepulis LPage RA2023-06-202022-04-122022-04-082023-06-2012/04/2022Nutrients, 2022, 14 (8)https://hdl.handle.net/10179/18315The New Zealand pine bark extract (Enzogenol®) has previously been shown to elicit acute hypoglycaemic effects in humans. The present study investigated the underlying mechanisms of Enzogenol® in reducing postprandial glucose in humans. The potential inhibitory action of Enzogenol® against digestive enzymes: α-amylase and α-glucosidase, and dipeptidyl peptidase-4 (DPP-4) enzyme was determined. Enzogenol® demonstrated the ability to inhibit all three enzymes: α-amylase enzyme activity (IC50 3.98 ± 0.11 mg/mL), α-glucosidase enzyme activity (IC50 13.02 ± 0.28 μg/mL), and DPP-4 enzyme activity (IC50 2.51 ± 0.04 mg/mL). The present findings indicate the potential for Enzogenol® to improve postprandial glycaemia by delaying carbohydrate digestion via the inhibition of digestive enzymes (α-amylase and α-glucosidase), and enhancing the incretin effect via inhibiting the dipeptidyl-peptidase-4 enzyme. The inhibitory actions of Enzogenol® on enzymes should therefore be further validated in humans for its potential use in type 2 diabetes mellitus prevention and management.functional foodhyperglycaemiahypoglycaemic effectsimpaired glycaemic controlincretin effectpolyphenolstarch inhibitionDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsFlavonoidsGlycoside Hydrolase InhibitorsHumansNew ZealandPinusPlant BarkPlant ExtractsQuercetinalpha-Amylasesalpha-GlucosidasesJournal article10.3390/nu140815964528382072-6643Massey_Dark0908 Food Sciences1111 Nutrition and Dietetics